4SC AG
4SC AG: Subgroup analysis suggests survival benefit in patients with advanced liver cancer treated with resminostat
4SC AG / Key word(s): Study results 05.10.2016 10:32 Disclosure of an inside information according to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- 4SC AG: Subgroup analysis suggests survival benefit in patients with advanced liver cancer treated with resminostat Planegg-Martinsried, Germany, 5 October 2016 - 4SC AG (4SC, FSE Prime Standard: VSC) and its development partner Yakult Honsha Co., Ltd. (Yakult Honsha) retrospectively analyzed the data of the randomized, multicenter Phase II study, conducted by Yakult Honsha in Japan and South Korea. The study investigated the effect of 4SC's epigenetic cancer drug resminostat in combination with the standard of care drug sorafenib compared with sorafenib monotherapy as a potential novel first-line treatment for patients with advanced liver cancer (hepatocellular carcinoma, HCC). Treatment with resminostat in combination with sorafenib demonstrated a substantial overall survival (OS) benefit compared with sorafenib monotherapy in a large subgroup comprised of 84 patients (50 % of all patients in the study) with a greater than median platelet count at study entry. As overall survival (OS) is the most relevant clinical endpoint in advanced HCC, the findings of the subgroup analysis provide important knowledge for the future clinical development of resminostat in combination with sorafenib in this indication. Based on these results, 4SC and Yakult are currently discussing their plans for continued clinical development of resminostat. The results of the study will be published by Yakult Honsha and the investigators at an upcoming scientific conference. --------------------------------------------------------------------------- Information and Explanation of the Issuer to this News: About 4SC 4SC (www.4sc.com) is a biotech company dedicated to the research and development of small-molecule drugs focused on epigenetic mechanisms of action for the treatment of cancers with high unmet medical needs. These drugs are intended to provide innovative treatment options for cancer patients that are more tolerable and efficacious than existing therapies, provide a better quality of life and offer increased life expectancy. The Company's pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had 50 employees as of 30 June 2016. 4SC has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005. Forward-looking information Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward- looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. 4SC Corporate Communications & Investor Relations Dr Anna Niedl, anna.niedl@4sc.com, +49 89 700763-66 Wolfgang Güssgen, wolfgang.guessgen@4sc.com, +49 89 700763-73 MC Services Katja Arnold, katja.arnold@mc-services.eu, +49 89 210228-40 The Ruth Group Carol Ruth, cruth@theruthgroup.com, +1 646 536 7004 05.10.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: 4SC AG Am Klopferspitz 19a 82152 Planegg-Martinsried Germany Phone: +49 (0)89 7007 63-0 Fax: +49 (0)89 7007 63-29 E-mail: public@4sc.com Internet: www.4sc.com ISIN: DE000A14KL72 WKN: A14KL7 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden